Why unloved investments deserve more attention

'WYSIATI' behavioural phenomenon among investors

clock • 4 min read

It is easy to buy well-loved investments. The US stockmarket, for example, offers companies such as Apple, Microsoft, Tesla, and Google parent Alphabet - all of which have well-known, well-loved products and well-known, well-loved stocks.

We might excuse investors for thinking the US stockmarket will only ever go up, given its performance in recent years. Yet, of course, that is not true. Buying these stocks today - or continuing to hold them - can feel like a good idea because of a behavioural phenomenon known as WYSIATI - What You See Is All There Is. What investors see in these companies is strong past performance - so strong that it is easy to then substitute a hard question ('What investments will likely do well in the future?') with an easy question ('What investments do I want to own?'). Companies and sectors...

To continue reading this article...

Join Investment Week for free

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

More on Specialist

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

‘Dedicated specialists’

James Baxter-Derrington
clock 06 April 2023 • 4 min read
European private equity yet to spend €270bn worth of capital

European private equity yet to spend €270bn worth of capital

Deployment of capital expected

Kathleen Gallagher
clock 04 January 2023 • 1 min read
Early-stage biopharma: An opportunity for strategic investment

Early-stage biopharma: An opportunity for strategic investment

Disproportionately smaller investment

Ali H. Munawar
clock 10 August 2022 • 4 min read
Trustpilot